Boehringer lngelheim Therapeutics GmbH

Founded in 1971, Boehringer Ingelheim Therapeutics formerly known as Labor Dr. Merk & Kollegen is based in Ochsenhausen, Germany and was a family owned company, performing R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments before being acquired by Boehringer Ingelheim in 2021. Before, the company worked as an excellent service provider for analytical testing.

All studies with drug regulatory status are performed in compliance with current GxP regulations: preclinical development is performed in compliance with GLP and drug substances are manufactured in compliance with GMP requirements.